{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:41:08Z","timestamp":1790286068312,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["438079"],"award-info":[{"award-number":["438079"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005324","name":"Universidad Aut\u00f3noma de San Luis Potos\u00ed","doi-asserted-by":"publisher","award":["C-891\/2018"],"award-info":[{"award-number":["C-891\/2018"]}],"id":[{"id":"10.13039\/501100005324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1099452"],"award-info":[{"award-number":["APP1099452"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1117065"],"award-info":[{"award-number":["APP1117065"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.xphs.2020.02.018","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T11:19:53Z","timestamp":1582802393000},"page":"2070-2078","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Population Pharmacokinetics and Dosing Recommendations of Levetiracetam in Adult and Elderly Patients With Epilepsy"],"prefix":"10.1016","volume":"109","author":[{"given":"Mar\u00eda Patricia","family":"Hern\u00e1ndez-Mitre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna Edith","family":"Medell\u00edn-Garibay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ildefonso","family":"Rodr\u00edguez-Leyva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian Jazm\u00edn","family":"Rodr\u00edguez-Pinal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Zaraz\u00faa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helgi Helene","family":"Jung-Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Romano-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa del Carmen","family":"Mil\u00e1n-Segovia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.xphs.2020.02.018_bib1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1358\/mf.2003.25.2.723686","article-title":"The pharmacokinetic characteristics of levetiracetam","volume":"25","author":"Patsalos","year":"2003","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"10.1016\/j.xphs.2020.02.018_bib2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0163-7258(99)00052-2","article-title":"Pharmacokinetic profile of levetiracetam: toward ideal characteristics","volume":"85","author":"Patsalos","year":"2000","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.xphs.2020.02.018_bib3","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00007691-200306000-00016","article-title":"Therapeutic drug monitoring of newer antiepileptic drugs","volume":"25","author":"Johannessen","year":"2003","journal-title":"Ther Drug Monit"},{"issue":"1","key":"10.1016\/j.xphs.2020.02.018_bib4","first-page":"17","article-title":"The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come?","volume":"5","author":"Perucca","year":"2003","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.xphs.2020.02.018_bib5","series-title":"The Treatment of Epilepsy","first-page":"516","article-title":"Levetiracetam","author":"Chong","year":"2016"},{"key":"10.1016\/j.xphs.2020.02.018_bib6","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1002\/jps.24350","article-title":"Biowaiver monographs for immediate release solid oral dosage forms: levetiracetam","volume":"104","author":"Petru\u0161evska","year":"2015","journal-title":"J\u00a0Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2020.02.018_bib7","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.4103\/0972-2327.128645","article-title":"Epilepsy in the elderly: special considerations and challenges","volume":"17","author":"Acharya","year":"2014","journal-title":"Ann Indian Acad Neurol"},{"issue":"7","key":"10.1016\/j.xphs.2020.02.018_bib8","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/j.1528-1167.2007.01043.x","article-title":"Effect of age and comedication on levetiracetam pharmacokinetics and tolerability","volume":"48","author":"Hirsch","year":"2007","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.xphs.2020.02.018_bib9","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1111\/j.1528-1167.2007.01272.x","article-title":"Generic products of antiepileptic drugs (AEDs): is it an issue?","volume":"48","author":"Bialer","year":"2007","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.xphs.2020.02.018_bib10","first-page":"134","article-title":"Generic AEDs: current standards and recommendations","volume":"5","author":"Berg","year":"2008","journal-title":"Univ Tenn Adv Stud Pharm"},{"issue":"7","key":"10.1016\/j.xphs.2020.02.018_bib11","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/epi.14439","article-title":"Generic antiepileptic drugs\u2014safe or harmful in patients with epilepsy?","volume":"59","author":"Holtkamp","year":"2018","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.xphs.2020.02.018_bib12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11060-009-0066-3","article-title":"Seizure risk in brain tumor patients with conversion to generic levetiracetam","volume":"98","author":"Armstrong","year":"2010","journal-title":"J\u00a0Neurooncol"},{"issue":"4","key":"10.1016\/j.xphs.2020.02.018_bib13","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/j.1528-1167.2011.03025.x","article-title":"Clinical experience with generic levetiracetam in people with epilepsy","volume":"52","author":"Chaluvadi","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.xphs.2020.02.018_bib14","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1345\/aph.1P765","article-title":"Generic substitution of levetiracetam resulting in increased incidence of breakthrough seizures","volume":"45","author":"Fitzgerald","year":"2011","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.xphs.2020.02.018_bib15","first-page":"129","article-title":"Fallo terape\u00fatico asociados al uso de Levetiracetam gen\u00e9rico: un reporte de 4 casos","volume":"27","author":"Granados","year":"2011","journal-title":"Acta Neurol Colomb"},{"issue":"182","key":"10.1016\/j.xphs.2020.02.018_bib16","first-page":"1","article-title":"Potential problems and recommendations regarding substitution of generic antiepileptic drugs: a systematic review of literature","volume":"5","author":"Atif","year":"2016","journal-title":"Springerplus"},{"key":"10.1016\/j.xphs.2020.02.018_bib17","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.2147\/DDDT.S138270","article-title":"Safety of switching from brand-name to generic levetiracetam in patients with epilepsy","volume":"11","author":"Bosak","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.xphs.2020.02.018_bib18","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.yebeh.2019.04.029","article-title":"Quality of life after switching to generic levetiracetam \u2013 a prospective comparative study","volume":"96","author":"Olsson","year":"2019","journal-title":"Epilepsy Behav"},{"issue":"1","key":"10.1016\/j.xphs.2020.02.018_bib19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40261-015-0351-1","article-title":"Safety of overnight switch from brand-name to generic levetiracetam","volume":"36","author":"Vari","year":"2016","journal-title":"Clin Drug Investig"},{"issue":"6","key":"10.1016\/j.xphs.2020.02.018_bib20","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/WNF.0000000000000250","article-title":"Switch from originator to equivalent drug in the era of generic antiepileptic drugs: study of keppra versus epitiram clinical equivalence","volume":"40","author":"Fanella","year":"2017","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.xphs.2020.02.018_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.seizure.2017.03.012","article-title":"Brand-to-generic levetiracetam switch in patients with epilepsy in a routine clinical setting","volume":"48","author":"Markoula","year":"2017","journal-title":"Seizure"},{"issue":"March","key":"10.1016\/j.xphs.2020.02.018_bib22","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.eplepsyres.2017.04.017","article-title":"Impact of generic substitution on levetiracetam serum concentration\u2014a prospective study in an outpatient setting","volume":"134","author":"Reimers","year":"2017","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.xphs.2020.02.018_bib23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.seizure.2018.06.020","article-title":"Brand name to generic substitution of levetiracetam in patients with epilepsy","volume":"60","author":"Gha-Hyun","year":"2018","journal-title":"Seizure"},{"issue":"4","key":"10.1016\/j.xphs.2020.02.018_bib24","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/ene.13568","article-title":"Brand-to-generic levetiracetam switching: a 4-year prospective observational real-life study","volume":"25","author":"Trimboli","year":"2018","journal-title":"Eur J Neurol"},{"issue":"8","key":"10.1016\/j.xphs.2020.02.018_bib25","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.braindev.2014.11.008","article-title":"The efficacy of levetiracetam for focal seizures and its blood levels in children","volume":"37","author":"Iwasaki","year":"2015","journal-title":"Brain Dev"},{"key":"10.1016\/j.xphs.2020.02.018_bib26","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.yebeh.2014.09.069","article-title":"The benefits of antiepileptic drug (AED) blood level monitoring to complement clinical management of people with epilepsy","volume":"42","author":"Stepanova","year":"2015","journal-title":"Epilepsy Behav"},{"issue":"7","key":"10.1016\/j.xphs.2020.02.018_bib27","first-page":"240","article-title":"Effective levetiracetam doses and serum concentrations: age effects","volume":"43","author":"Leppik","year":"2002","journal-title":"AES Proc Epilepsia"},{"key":"10.1016\/j.xphs.2020.02.018_bib28","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.3390\/ph3061909","article-title":"Therapeutic drug monitoring of the newer anti-epilepsy medications","volume":"3","author":"Krasowski","year":"2010","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.xphs.2020.02.018_bib29","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/FTD.0b013e31827c11e7","article-title":"Therapeutic drug monitoring of antiepileptic drugs by use of saliva","volume":"35","author":"Patsalos","year":"2013","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.xphs.2020.02.018_bib30","doi-asserted-by":"crossref","first-page":"149","DOI":"10.18433\/jpps30081","article-title":"Therapeutic drug monitoring of levetiracetam","author":"Jarvie","year":"2018","journal-title":"J\u00a0Pharm Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2020.02.018_bib31","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.seizure.2007.11.027","article-title":"Serum concentration\/dose ratio of levetiracetam before, during and after pregnancy","volume":"17","author":"Westin","year":"2008","journal-title":"Seizure"},{"issue":"4","key":"10.1016\/j.xphs.2020.02.018_bib32","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate","volume":"145","author":"Levey","year":"2006","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.xphs.2020.02.018_bib33","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A\u00a0new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.xphs.2020.02.018_bib34","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jchromb.2008.08.007","article-title":"Simple and validated HPLC-UV analysis of levetiracetam in deproteinized plasma of patients with epilepsy","volume":"873","author":"Contin","year":"2008","journal-title":"J\u00a0Chromatogr B Anal Technol Biomed Life Sci"},{"issue":"4","key":"10.1016\/j.xphs.2020.02.018_bib35","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/BF01060893","article-title":"Some suggestions for measuring predictive performance","volume":"9","author":"Sheiner","year":"1981","journal-title":"J\u00a0Pharmacokinet Biopharm"},{"issue":"6","key":"10.1016\/j.xphs.2020.02.018_bib36","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2165\/00003088-200746060-00004","article-title":"Population pharmacokinetics of levetiracetam in Japanese and Western adults","volume":"46","author":"Pigeolet","year":"2007","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.xphs.2020.02.018_bib37","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2133\/dmpk.DMPK-13-RG-045","article-title":"Development of an integrated population pharmacokinetic model for oral levetiracetam in populations of various ages and ethnicities","volume":"29","author":"Toublanc","year":"2014","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.xphs.2020.02.018_bib38","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.eplepsyres.2017.02.011","article-title":"Population pharmacokinetics and dose-response relationship of levetiracetam in adult patients with epilepsy","volume":"132","author":"Rhee","year":"2017","journal-title":"Epilepsy Res"},{"issue":"5","key":"10.1016\/j.xphs.2020.02.018_bib39","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2165\/00003088-200847050-00004","article-title":"Retrospective population pharmacokinetic analysis of levetiracetam in children and adolescents with epilepsy. Dosing recommendations","volume":"47","author":"Toublanc","year":"2008","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.xphs.2020.02.018_bib40","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/j.1528-1167.2008.01974.x","article-title":"Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy","volume":"50","author":"Chhun","year":"2009","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.xphs.2020.02.018_bib41","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/aps.2012.57","article-title":"Population pharmacokinetics modeling of levetiracetam in Chinese children with epilepsy","volume":"33","author":"Wang","year":"2012","journal-title":"Acta Pharmacol Sin"},{"issue":"3","key":"10.1016\/j.xphs.2020.02.018_bib42","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/jcpt.12658","article-title":"Population pharmacokinetics of levetiracetam in neonates with seizures","volume":"43","author":"Lima-Rogel","year":"2018","journal-title":"J\u00a0Clin Pharm Ther"},{"issue":"4","key":"10.1016\/j.xphs.2020.02.018_bib43","doi-asserted-by":"crossref","first-page":"276","DOI":"10.5649\/jjphcs1975.21.276","article-title":"Advantage of body surface area on dose adjustment of antiepileptic drugs","volume":"21","author":"Kihira","year":"1995","journal-title":"Jpn J Hosp Pharm"},{"issue":"5","key":"10.1016\/j.xphs.2020.02.018_bib44","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/FTD.0000000000000550","article-title":"Influence of sex, age, and weight on levetiracetam pharmacokinetics","volume":"40","author":"Alzueta","year":"2018","journal-title":"Ther Drug Monit"},{"issue":"11","key":"10.1016\/j.xphs.2020.02.018_bib45","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2165\/00003088-200443110-00002","article-title":"Clinical pharmacokinetics of levetiracetam","volume":"43","author":"Patsalos","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.xphs.2020.02.018_bib46","series-title":"USP 38 Monographs. Levetiracetam Tablets","year":"2015"},{"issue":"12","key":"10.1016\/j.xphs.2020.02.018_bib47","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1046\/j.1528-1157.2001.41300.x","article-title":"Pharmacokinetic study of levetiracetam in children","volume":"42","author":"Pellock","year":"2001","journal-title":"Epilepsia"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354920301180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354920301180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:28:41Z","timestamp":1758360521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354920301180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0022354920301180"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2020.02.018","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population Pharmacokinetics and Dosing Recommendations of Levetiracetam in Adult and Elderly Patients With Epilepsy","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2020.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}